Poly(I:C) drives type i IFN- and TGFΒ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis

Journal of Investigative Dermatology

Volumn 130, Issue 11, 2010, Pages 2583-2593

  Farina, Giuseppina A ^a   York, Michael R ^a   Di Marzio, Michael ^a   Collins, Cindy A ^a   Meller, Stephan ^b   Homey, Bernhard ^b   Rifkin, Ian R ^a   Marshak Rothstein, Ann ^c   Radstake, Timothy R D J ^d   Lafyatis, Robert ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SKIN; SKIN FIBROBLAST; SKIN FIBROSIS; SKIN INFLAMMATION; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 77957940944     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.200     Document Type: Article

References (49)

1. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783-801
2. Aliprantis AO, Wang J, Fathman JW et al. (2007) Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 104:2827-30
3. Belperio JA, Dy M, Burdick MD et al. (2002) Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 27:419-27
4. Black CM, Silman AJ, Herrick AI et al. (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42:299-305
5. Crow MK, Kirou KA, Wohlgemuth J (2003) Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36:481-90
6. Distler O, Pap T, Kowal-Bielecka O et al. (2001) Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 44:2665-78
7. Doyle SE, O'Connell R, Vaidya SA et al. (2003) Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4. J Immunol 170:3565-71
8. Farina G, Lafyatis D, Lemaire R et al. (2010) A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 62:580-8
9. Farina G, Lemaire R, Pancari P et al. (2009) Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 68:435-41
10. Faure E, Equils O, Sieling PA et al. (2000) Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem 275:11058-63
11. Fineschi S, Goffin L, Rezzonico R et al. (2008) Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 58:3913-23
12. Galindo M, Santiago B, Rivero M et al. (2001) Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte che-moattractant protein 1 expression. Arthritis Rheum 44:1382-6
13. Guillot L, Medjane S, Le-Barillec K et al. (2004) Response of human pulmonary epithelial cells to lipopolysaccharide involves toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem 279:2712-8
14. Hua J, Kirou K, Lee C et al. (2006) Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 54:1906-16
15. Jelaska A, Arakawa M, Broketa G et al. (1996) Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 39:1338-46
16. Jelaska A, Korn JH (2000) Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43:2230-9
17. Jiang D, Liang J, Fan J et al. (2005) Regulation of lung injury and repair by tolllike receptors and hyaluronan. Nat Med 11:1173-9
18. Kim D, Peck A, Santer D et al. (2008) Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 58:2163-73
19. Kissin EY, Merkel PA, Lafyatis R (2006) Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 54:3655-60
20. Kleinman ME, Yamada K, Takeda A et al. (2008) Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-7
21. Kluwe J, Mencin A, Schwabe RF (2009) Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 87:125-38
22. Kollisch G, Kalali BN, Voelcker V et al. (2005) Various members of the tolllike receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114:531-41
23. Kolumam GA, Thomas S, Thompson LJ et al. (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202:637-50
24. Lande R, Gregorio J, Facchinetti V et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564-9
25. Lee CG, Cho SJ, Kang MJ et al. (2004) Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 200:377-89
26. Lee CG, Homer RJ, Zhu Z et al. (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809-21
27. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-5
28. Meller S, Winterberg F, Gilliet M et al. (2005) Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52:1504-16
29. Meneghin A, Hogaboam CM (2007) Infectious disease, the innate immune response, and fibrosis. J Clin Invest 117:530-8
30. Miettinen M, Sareneva T, Julkunen I et al. (2001) IFNs activate toll-like receptor gene expression in viral infections. Genes Immun 2:349-55
31. Milano A, Pendergrass SA, Sargent JL et al. (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3:e2696
32. Morris GE, Parker LC, Ward JR et al. (2006) Cooperative molecular and cellular networks regulate toll-like receptor-dependent inflammatory responses. FASEB J 20:2153-5
33. Negishi H, Osawa T, Ogami K et al. (2008) A critical link between toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci USA 105:20446-51
34. Pierer M, Rethage J, Seibl R et al. (2004) Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by toll-like receptor 2 ligands. J Immunol 172:1256-65
35. Proost P, Verpoest S, Van de Borne K et al. (2004) Synergistic induction of CXCL9 and CXCL11 by toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J Leukoc Biol 75:777-84
36. Sanda C, Weitzel P, Tsukahara T et al. (2006) Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 26:462-72
37. Seki E, De Minicis S, Osterreicher CH et al. (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13:1324-32
38. Sugiura H, Ichikawa T, Koarai A et al. (2009) Activation of toll-like receptor 3 augments myofibroblast differentiation. Am J Respir Cell Mol Biol 40:654-62
39. Takeuchi O, Akira S (2009) Innate immunity to virus infection. Immunol Rev 227:75-86
40. van der Fits L, Mourits S, Voerman JS et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182:5836-45
41. van der Fits L, van der Wel LI, Laman JD et al. (2004) In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 122:51-60
42. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 66:1008-14
43. Varga J (1997) Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically? Arch Dermatol 133:637-42
44. Yamamoto T, Takagawa S, Katayama I et al. (1999) Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 92:6-13
45. Yamana J, Santos L, Morand E (2009) Enhanced induction of LPS-induced fibroblast MCP-1 by interferon-gamma: involvement of JNK and MAPK phosphatase-1. Cell Immunol 255:26-32
46. York MR, Nagai T, Mangini AJ et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56:1010-20
47. Yoshimura T, Takahashi M (2007) IFN-gamma-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands. J Immunol 179:1942-9
48. Zhang Y, McCormick LL, Desai SR et al. (2002) Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168:3088-98
49. Zhang Y, McCormick LL, Gilliam AC (2003) Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 121: 713-9